Selective serotonin-reuptake inhibitor-induced movement disorders

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Medicine

Background:

• Selective serotonin-reuptake inhibitors (SSRIs) are widely prescribed antidepressants.
• Movement disorders are potential adverse effects associated with various medications.
• Understanding the link between SSRIs and movement disorders is critical for patient safety.

Purpose of the Study:

• To compile and evaluate data on SSRI-associated movement disorders.
• To characterize the onset, duration, treatment, and outcomes of these reactions.
• To identify potential predisposing factors for SSRI-induced movement disorders.

Main Methods:

• Comprehensive literature search of adverse drug reaction resources and databases (MEDLINE, EmBASE, etc.).
• Solicitation of reports from SSRI manufacturers and Health Canada.
• Classification of movement disorder cases based on predefined diagnostic criteria.

Main Results:

• 127 published reports identified: akathisia (30), dystonia (19), dyskinesia (12), tardive dyskinesia (6), parkinsonism (25), mixed (15), and bruxism (10).
• Manufacturer data revealed higher numbers for akathisia (49), dystonia (44), dyskinesia (208), tardive dyskinesia (76), and parkinsonism (516).
• Treatment strategies included SSRI discontinuation, dosage reduction, or addition of benzodiazepines, beta-blockers, or anticholinergics.

Conclusions:

• SSRI use is associated with movement disorders, potentially as a direct effect or exacerbation of underlying conditions.
• Predisposing factors include neuroleptic use, existing neurologic diagnoses, or prior movement disorders.
• Clinicians must recognize and manage these reactions promptly to prevent patient morbidity.